Last reviewed · How we verify
Diclofenac + Omeprazole
Diclofenac inhibits prostaglandin synthesis to reduce inflammation and pain, while omeprazole suppresses gastric acid production to protect against NSAID-induced ulcers.
Diclofenac inhibits prostaglandin synthesis to reduce inflammation and pain, while omeprazole suppresses gastric acid production to protect against NSAID-induced ulcers. Used for Rheumatoid arthritis with gastric protection, Osteoarthritis with gastric protection, Ankylosing spondylitis with gastric protection.
At a glance
| Generic name | Diclofenac + Omeprazole |
|---|---|
| Sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. |
| Drug class | NSAID + Proton pump inhibitor combination |
| Target | COX-1/COX-2 (diclofenac); H+/K+-ATPase (omeprazole) |
| Modality | Small molecule |
| Therapeutic area | Rheumatology / Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) that blocks cyclooxygenase (COX) enzymes, reducing prostaglandin production and thereby decreasing inflammation, pain, and fever. Omeprazole is a proton pump inhibitor that irreversibly blocks H+/K+-ATPase in gastric parietal cells, significantly reducing gastric acid secretion. This combination is designed to provide NSAID efficacy while mitigating the gastrointestinal toxicity (ulcers, bleeding) associated with chronic NSAID use.
Approved indications
- Rheumatoid arthritis with gastric protection
- Osteoarthritis with gastric protection
- Ankylosing spondylitis with gastric protection
- Acute pain conditions requiring NSAID therapy with gastroprotection
Common side effects
- Headache
- Dyspepsia
- Abdominal pain
- Diarrhea
- Nausea
- Dizziness
Key clinical trials
- KF2022#4-trial: Effects of a Beta Blocker and NSAID on CYP Mediated Drug Metabolism (NA)
- PROUD Study - Preventing Opioid Use Disorders (PHASE4)
- Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With Arthritis (PHASE4)
- Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors (PHASE1)
- Non-Steroidal Anti-inflammatory Drugs in Axial Spondyloarthritis (PHASE4)
- Dabigatran in an Interaction Probe Drug Cocktail (PHASE1)
- A Study to Evaluate the Effects of ASA404 Alone or in Combination With Taxane-based Chemotherapies on the Pharmacokinetics of Drugs in Patients With Advanced Solid Tumor Malignancies (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: